title: Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine.
abstract: Plasmodium falciparum apical membrane antigen 1 (AMA1) is an asexual blood-stage vaccine candidate against the malaria parasite. AMA1-C1/ISA 720 refers to a mixture of recombinant AMA1 proteins representing the FVO and 3D7 alleles in 1:1 mass ratio, formulated with Montanide(®) ISA 720 as a water-in oil emulsion. In order to develop the AMA1-C1/ISA 720 vaccine for human use, it was important to determine the shelf life of this formulation. Previously it was found 267 mM glycine stabilized the proteins in Montanide(®) ISA 720 formulations for a short period of time at 2-8°C [25]. We now test the long term stability of AMA1-C1 at 10 and 40 μg/mL formulated with Montanide(®) ISA 720 with 50mM glycine as a stabilizer. Stability of AMA1-C1/ISA 720 at different time points following formulation (0, 5, 12 or 18 months) was evaluated by determining the mean particle size (diameter of the mean droplet volume), total protein content by a Modified Lowry assay, identity and integrity using western blot and SDS-PAGE. Our results showed that the mean particle size of these emulsions increased over time, whereas protein content, as determined by an ELISA method using a monoclonal antibody against penta-his, decreased over time. For the 10 μg/mL AMA1-C1/ISA 720 vaccine, the protein content was 6.5±2.2 μg/mL, and for the 40 μg/mL AMA1-C1/ISA 720 vaccine, the protein content was only 8.2±2.3 μg/mL after 18 months of storage at 2-8°C. These results suggest that the integrity of the protein was affected by long-term storage. The results of the present study indicate that the AMA1-C1/ISA 720 emulsion was unstable after 12 months of storage, after which AMA1-C1 proteins were partially degraded.
authors: Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Disease, National Institutes of Health, 5640 Fishers Lane, Rockville, MD 20852, USA. dzhu@niaid.nih.gov
authors: Daming
authors: D
authors: Zhu
authors: Holly
authors: H
authors: McClellan
authors: Weili
authors: W
authors: Dai
authors: Elizabeth
authors: E
authors: Gebregeorgis
authors: Mary Anne
authors: MA
authors: Kidwell
authors: Joan
authors: J
authors: Aebig
authors: Kelly M
authors: KM
authors: Rausch
authors: Laura B
authors: LB
authors: Martin
authors: Ruth D
authors: RD
authors: Ellis
authors: Louis
authors: L
authors: Miller
authors: Yimin
authors: Y
authors: Wu
mesh_terms: D000276:Adjuvants, Immunologic / Q000737:chemistry; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D000953:Antigens, Protozoan / Q000008:administration & dosage / Q000276:immunology*; D004355:Drug Stability; D004356:Drug Storage; D005260:Female; D005998:Glycine / Q000737:chemistry* / Q000276:immunology; D017780:Malaria Vaccines / Q000008:administration & dosage / Q000737:chemistry* / Q000276:immunology; D016778:Malaria, Falciparum / Q000276:immunology / Q000517:prevention & control; D008353:Mannitol / Q000031:analogs & derivatives* / Q000737:chemistry / Q000276:immunology; D008565:Membrane Proteins / Q000008:administration & dosage / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009829:Oleic Acids / Q000737:chemistry* / Q000276:immunology; D010316:Particle Size; D010963:Plasmodium falciparum / Q000276:immunology; D015800:Protozoan Proteins / Q000008:administration & dosage / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000737:chemistry / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D017780:Malaria Vaccines; D008565:Membrane Proteins; D009829:Oleic Acids; D015800:Protozoan Proteins; D014614:Vaccines, Synthetic; C090077:apical membrane antigen I, Plasmodium; C001681:mannide monooleate; D008353:Mannitol; D005998:Glycine